Welcome to our dedicated page for MYND LIFE SCIENCS news (Ticker: MYNDF), a resource for investors and traders seeking the latest updates and insights on MYND LIFE SCIENCS stock.
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuropharmaceutical and novel drug development, diagnostics, and vaccines. MYND is dedicated to commercializing proprietary biomarker diagnostic tests and novel therapeutics for patients battling with Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD), and other neuro-inflammatory disorders. The company is currently in discussions regarding its unsecured convertible debentures and has formed a special committee to evaluate alternatives. Moreover, MYND has recently announced a potential merger with Cava Healthcare Inc, aiming to create a powerful new commercial entity by combining their patents and expertise to revolutionize treatments for neurological and inflammatory diseases.
MYND Life Sciences has completed the acquisition of intellectual property rights to use psychedelics for treating dementia, including Alzheimer's disease, from Cava Healthcare. This acquisition is expected to enhance MYND's capabilities in psilocybin-assisted therapy, which is aimed at addressing a condition that affects 44 to 50 million people globally. MYND issued 450,000 shares at $0.85 each and made a cash payment of $120,000. An annual royalty of $240,000 or 4% of net sales will also be paid. The acquisition positions MYND as a leader in psychedelic therapeutics for dementia.
MYND Life Sciences Inc. (CSE: MYND, OTC: MYNDF) announced the completion of its National Phase filing for a Patent Cooperation Treaty (PCT) application related to a method of immune modulation targeting a specific gene. CEO Dr. Lyle Oberg stated that building a solid intellectual property portfolio is crucial for long-term shareholder value. The PCT enables simultaneous patent protection across multiple countries. MYND aims to advance its drug pipeline to file for Innovative New Drug (IND) application. The company has also engaged Hybrid Financial Ltd. for marketing services.
MYND Life Sciences has received a grant of $45,600 from the Government of Canada to support research on the effects of psilocybin in treating brain diseases. The funding will aid a project titled Phytochemical-analog(s) as a novel method for management of treatment-resistant depression, running from November 2021 to March 2022. The project aims to explore how psilocybin analogs can modulate brain function by targeting specific gene pathways. The company is committed to advancing neuro-pharmaceutical innovations.
MYND Diagnostics, a subsidiary of MYND Life Sciences, has launched a clinical validation study for its proprietary MAP biomarker test aimed at aiding the diagnosis and monitoring of Multiple Sclerosis (MS). The study, expected to start in Q1 2022, will quantify MAP levels in MS patients' blood samples compared to controls. Successful results could lead to an FDA approval submission in H2 2022, making the test available through healthcare providers. The global MS therapeutic market was valued at $22.99 billion in 2018 and is projected to reach $28 billion by 2026.
MYND Life Sciences has announced the initiation of a clinical validation study for its proprietary biomarker testing in Alzheimer's Disease (AD) diagnostics. The study, conducted by its subsidiary MYND Diagnostics, aims to utilize the MAP biomarker to enhance early diagnosis and monitoring of AD. The validation is set to commence in Q1 2022, with anticipated FDA submission for approval in H2 2022. Currently, around 44 million people are affected by AD worldwide, and the diagnostics market was valued at USD 6.6 billion in 2020, projected to reach USD 9 billion by 2026.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTC: RVLWF) has signed a binding letter of intent with MYND Diagnostics Inc. for a clinical research collaboration. This aims to study the relationship between diagnostic results using MYND's proprietary anti-inflammatory peptide biomarker (MAP) and improved patient outcomes in mental health. The initial clinical trials will focus on patients with post-COVID-19 mental health symptoms, utilizing Revitalist's network of over 2,300 patients. The goal is to submit MAP to the FDA for approval in Q2 2022, enhancing diagnostic accuracy and treatment efficacy.
MYND Life Sciences Inc. (CSE: MYND, OTC: MYNDF) announces a binding LOI with Revitalist Lifestyle and Wellness to collaborate on clinical research. This partnership aims to study the MAP biomarker’s effectiveness in diagnosing and monitoring mental health, particularly in patients experiencing post-COVID-19 symptoms like 'Brain Fog.' The objective is to provide a more objective diagnostic tool for healthcare providers and to gain FDA approval by Q2 2022. MYND anticipates generating revenue through research and aims to expand its mental health studies leveraging Revitalist's extensive clinic network.
MYND Life Sciences Inc. has announced significant changes to its Board of Directors. Aaron Bowden, a founding board member, has resigned, with the company expressing gratitude for his contributions. In his place, Scott L. Nicoll has been appointed as an independent director and interim Chair of the Audit Committee. Nicoll brings extensive legal and governance experience as a partner at Panorama Legal LLP and chair of Food Banks BC. The board is optimistic that his leadership will enhance the company's governance.
MYND Life Sciences (CSE: MYND, OTC: MYNDF) announced its agreement to acquire intellectual property rights from Cava Healthcare for the use of psychedelics in treating dementia, including Alzheimer's disease. The deal involves 450,000 common shares at a deemed price of $0.85 each and $120,000 in cash. MYND will also pay a yearly royalty of $240,000 or 4% of net sales. This acquisition aims to strengthen MYND's position in psychedelic treatments for neurodegenerative conditions.
MYND Diagnostics Inc. announced its participation in a proposed clinical trial to evaluate the efficacy of psilocybin-assisted psychotherapy for treatment-resistant depression (TRD). The trial aims to secure a portion of a $15 million fund from the Australian government and will employ MYND's proprietary biomarker technology. Led by Professor Paul Fitzgerald of Monash University, the phase 2b trial will assess the safety and efficacy of psilocybin treatments. If successful, it could lead to a multi-site phase 3 trial for regulatory approval within 12 months.
FAQ
What is the current stock price of MYND LIFE SCIENCS (MYNDF)?
What is the market cap of MYND LIFE SCIENCS (MYNDF)?
What is MYND Life Sciences Inc. focused on?
Which disorders does MYND target with its therapeutics?
What recent announcement did MYND make about its convertible debentures?
What is the purpose of the special committee formed by MYND?
What potential merger has MYND announced recently?